Best mode for treating hard cataracts

Article

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

The "multiburst" mode of bimanual microincision phacoemulsification machines is unsuitable for treating cataracts with a nuclear density of Grade 3 and above, according to study results published in the July 2008 issue of Clinical & Experimental Ophthalmology.

Liu Yizhi, MD, PhD of the Zhongshan Ophthalmic Center at Sun Yat-sen University, Guangzhou, China and colleagues assessed the effects on "hard" cataracts of the "multiburst" and "shortburst" settings of the Sovereign phaco machine (AMO) in comparison to the settings on the Whitestar technology platform (AMO).

The differences between the three groups were statistically significant. The ultrasonic power was highest for the Whitestar, followed by Sovereign's shortpulse and then the multiburst setting. The multiburst setting had the highest ultrasonic power release time, effective phaco time and rate of endothelial cell loss; the group displaying the lowest levels of these variables was the Whitestar group. In the multiburst group, there was also one case of wound burn and three eyes displaying abnormal fluctuations in the anterior chamber depth.

Based on these data, the research team concluded that, while Sovereign's multiburst mode was an unreliable method of performing this type of surgery, Whitestar technology had the best results of the study and offers an acceptable alternative.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.